Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy

Trafficking to Tumors for Immunotherapy Gene Therapy to Manipulate Effector T Cell

Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.

Adoptive T-cell therapy with CD8(+) CTLs is often characterized by poor persistence of the transferred T cells and limited effector responses. Improved persistence and therapeutic efficacy have been noted when antigen-activated CD8(+) T cells express properties of memory cells. The current study was undertaken to more precisely characterize the development of memory-like CD8(+) T cells from sho...

Advances in gene therapy and immunotherapy for brain tumors.

PURPOSE OF REVIEW Treatments for malignant glioma, the most lethal and common primary brain tumor, are undergoing a dramatic evolution led by biological and technological advancements. This review focuses on developments in novel areas of gene therapy and immunotherapy, particularly vaccine development. RECENT FINDINGS Advances in basic research of antigen-presenting cells and applications of...

Intracranial Tumors Effective Immunotherapy of Established Effector T Cells Is Sufficient to Mediate Cross-Presentation of Tumor Antigens to

Effector CD8 T cell trafficking within the liver.

CD8 T cells play a critical role in several pathological conditions affecting the liver, most notably viral hepatitis. Accordingly, understanding the mechanisms that modulate the intrahepatic recruitment of CD8 T cells is of paramount importance. Some of the rules governing the behavior of these cells in the liver have been characterized at the population level, or have been inferred by studyin...